Test Update // Report Improvements: Whole Genome & Exome Sequencing

Dear Valued Clients, 

Thank you for your continued trust in Baylor Genetics as your genetic testing partner. As we continue to upgrade and refine our test menu and services, we want you to be the first to know about changes that may affect your testing experience with us. 

Effective May 22, 2023, Baylor Genetics implemented significant improvements to our reports for Whole Genome & Exome Sequencing (WGS/WES). We are confident that these changes will provide a better customer experience for you and your patients.  

Our goal was to improve the readability of these reports and provide clear, actionable results. The updated reports are easier to read, have an intuitive flow, and have new features that can support the clinical care of your patients. Improvements include:  

• All high-priority information is located on the first two pages of the report, including: 
  • Clinical indication  
  • Results  
  • Results summary  
  • Interpretation of phenotype related findings  
  • Recommendations  
  • Additional findings  

• Improved order of information, which tells the testing and report story.  
  • Why was the test performed?  
  • What did we find?  
  • What do the results mean?  
  • What are the next steps?  

• All tables have been condensed and content aligned for easy readability.  
• Acronyms are now spelled out to improve understanding.  
• For Research Findings, the table header and description information have been updated to clarify what is being reported.  

We have also updated our requisitions and consents for WGS and WES* to add more flexibility in ordering options. Providers now have three options available to add to the report:   

1. ACMG secondary findings  
2. Medically significant incidental findings  
3. Research findings  

You will see the updates in these reports:  

• Whole Genome Sequencing  
  • Proband, Duo, Trio  
  • Rapid Options: Proband, Duo, Trio  
  • WGS Reanalysis  

• Whole Exome Sequencing  
  • Proband, Duo, Trio, BluePrint Panels, Prenatal, Adult  
  • Rapid Options: Proband, Duo, Trio  
  • WES Reanalysis  

We know these changes will make it easier for you to get the information you need from your reports. If you have any questions regarding this update, please contact our client services team at 1-800-411-4636 or email us at [email protected].  

Thank you for your continued trust and support. 

*The requisition name for WES is now “Whole Exome Sequencing (WES) Requisition.” It was formerly listed as “WES Advantage Requisition.”